An intention-to-treat analysis has shown that timing and duration of adjuvant chemotherapy can be optimized to allow full postoperative recovery for patients undergoing resection for pancreatic adenocarcinoma. This analysis included 985 eligible patients randomly assigned to one of two equally effective chemotherapy regimens; 68% of these patients completed the full course of chemotherapy (six cycles), whereas 30% completed one-to-five cycles. The best recurrence-free survival and overall survival was observed in patients who had received the full course of treatment. Among these patients, there was no difference in overall survival when treatment was started early (within 8 weeks of surgery) or later (up to 12 weeks after surgery).
References
Valle, J. W. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J. Clin. Oncol. 10.1200/JCO.2013.50.7657
Rights and permissions
About this article
Cite this article
Optimal timing for post-surgery chemotherapy. Nat Rev Clin Oncol 11, 120 (2014). https://doi.org/10.1038/nrclinonc.2014.9
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.9